ReviewAdvanced drug delivery reviews2016
Engineering cell-based therapies to interface robustly with host physiology.
Review in Advanced drug delivery reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Programmable synthetic receptors: the next-generation of cell and gene therapies.Signal transduction and targeted therapy · 2024Review
- Discovery and validation of human genomic safe harbor sites for gene and cell therapies.Cell reports methods · 2022Article
- Review
- Rewiring of endogenous signaling pathways to genomic targets for therapeutic cell reprogramming.Nature communications · 2020Article
- Elucidation and refinement of synthetic receptor mechanisms.Synthetic biology (Oxford, England) · 2020Article
- Cell-mediated and cell membrane-coated nanoparticles for drug delivery and cancer therapy.Cancer drug resistance (Alhambra, Calif.) · 2020Article
- Building with intent: technologies and principles for engineering mammalian cell-based therapies to sense and respond.Current opinion in biomedical engineering · 2017Article
- Multiplexing Engineered Receptors for Multiparametric Evaluation of Environmental Ligands.ACS synthetic biology · 2017Article
- Rewiring human cellular input-output using modular extracellular sensors.Nature chemical biology · 2017Article
- Calcium phosphate cements for bone engineering and their biological properties.Bone research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Engineered cell-based therapies comprise a rapidly growing clinical technology for treating disease by leveraging the natural capabilities of cells, including migration, information transduction, and biosynthesis and secretion. There now exists a substantial portfolio of intracellular and extracellular sensors that enable bioengineers to program cells to execute defined responses to specific changes in state or environmental cues. As our capability to construct more sophisticated cellular programs increases, assessing and improving the degree to which cell-based therapies perform as desired in vivo will become an increasingly important consideration and opportunity for technological advancement. In this review, we seek to describe both current capabilities and potential needs for building cell-based therapies that interface with host physiology in a manner that is robust - a phrase we use in this context to describe the achievement of therapeutic efficacy across a range of patients and implementations. We first review the portfolio of sensors and outputs currently available for use in cell-based therapies by highlighting key advancements and current gaps. Then, we propose a conceptual framework for evaluating and pursuing robust clinical performance of engineered cell-based therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.